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Abbreviations 
ACR     Acute cellular rejection 
AST      Aspartate aminotransferase 
ALT     alanine aminotransferase   
CNI      Calcineurin inhibitors 
CS    Corticosteroids 
CMV     Cytomegalovirus 
DM     Diabetes mellitus 
EC-MPS    Enteric-coated  mycophenolate sodium 
HCV    Hepatitis C virus 
INR     International Normalized Ratio  
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I-R     Ischemia-reperfusion injury 
MAP     Mean arterial pressure 
MMF     Mycophenolate mofetil 
NGT     Naso-gastric tube 
NODM     New onset- diabetes mellitus 
POD     Post-operative day 
OLT     Orthotopic liver transplantation 
ABSTRACT 
 
Background. Corticosteroids (CS) have always been part of the standard post-transplant 
immunosuppression to prevent and treat rejection. However, CS are associated with 
increased risk of infection, obesity, hypertension, hyperlipidemia, diabetes, and bone 
necrosis. They have also been implicated in accelerating Hepatitis C (HCV) recurrence post-
liver transplantation (OLT). This study assesses the safety and efficacy of completely CS-
free immunosuppressive regimen in adult OLT.  
Methods. A 2-year, prospective, randomized study of CS or no-CS immunosuppressive 
regimen with basiliximab, tacrolimus and enteric-coated mycophenolate sodium (EC-MPS) 
was performed in 39 patients (CS=20, group A; No-CS=19, group B). The CS cohort 
received intra-operative methylprednisolone 1 gram intravenously tapered and weaned off by 
6 months. HCV patients had HCV PCR pre-OLT, 0.5, 1, 3, 6 months post-OLT. Protocol 
liver biopsies were performed at OLT, 2 weeks, and 6 months post-OLT or when clinically 
indicated.  
Results. CS-responsive acute rejection occurred in one patient in each group. Patient survival 
rates at 1 year (100% vs. 94%), 3 and 5 years (85% vs. 63%) post-OLT were similar between 
group A and B, respectively. Death-censored graft survival rates at 1 year (100% vs. 100%), 
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3 and 5 years (85% vs. 79%) were also similar between group A and B, respectively. The 
risk of new onset DM, hypertension, hypercholesterolemia, and weight gain was similar 
between 2 groups.   
Conclusion.  Complete CS-avoidance with basiliximab, calcineurin inhibitor (CNI), and EC-
MPS is safe and effective as CS-containing immunosuppressive regimen in adult OLT.  
 
INTRODUCTION 
Corticosteroids (CS) have always been an integral part of standard post-transplant 
immunosuppression for prevention and treatment of rejection. First introduced in the early 
1950s, CS have been used widely since the first successful orthotopic liver transplantation 
(OLT) in 1967 (1).  CS exert potent immunosuppressive and anti-inflammatory effects 
through their action on leukocytes by stimulation or inhibition of gene transcription, altering 
gene expression responsible for mounting immune and inflammatory responses.   However, 
CS use has been shown to cause long-term adverse effects, which include diabetes, increased 
susceptibility to infection, obesity, hypertension, hyperlipidemia, osteopenia, cataracts and 
growth retardation in children. CS have also been implicated in accelerating Hepatitis C 
(HCV) recurrence post-OLT (2-3). Consequently, several clinical trials which adopted early 
CS reduction and cessation after OLT were conducted and showed no increase in safety risks 
(4-6). In recent years, a small but increasing proportion of transplant centers, including our 
group, have demonstrated that adult and pediatric OLT may be successfully performed with 
CS minimization (7-11).   
  Prior to this study the standard immunosuppressive protocol at Thomas Jefferson 
University Hospital (TJUH) for OLT recipients included basiliximab induction and CS 
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intraoperatively, followed by calcineurin inhibitor (CNI), mycophenolate mofetil (MMF), 
and CS maintenance therapy.  
 
RESULTS  
Between February 2006 and November 2007, forty adult OLT recipients were 
enrolled in the study and 20 recipients were randomized to each group. One recipient in the 
CS-free group required a re-transplantation for hepatic artery thrombosis on post-OLT day 
16. Since he expired within 10 days after re-transplantation, follow up data was short and 
untenable and therefore, he was excluded from the study analysis.   
The mean overall follow-up was 47.3 months as of July 2011. Donor characteristics 
were comparable between the two groups (Table 1). Other than a significantly higher mean 
recipient age and longer mean hospital stay in group B compared to group A, recipient 
demographics and peri-operative data were similar between the two groups. There were 3 
outliers in group B with mean hospital stay of 67.7 (range: 43-89) days. One had a protracted 
surgical ICU stay due to prolonged ventilator dependence, atrial fibrillation, and poor mental 
status. Another patient had ventilator-dependent adult respiratory distress syndrome, hepato-
pulmonary syndrome, acute renal failure, sepsis, and massive colonic bleeding.  The third 
patient had a MELD score of 35 at OLT with hepato-renal syndrome (Table 1). 
Primary end points 
There was no significant difference in patient and death-censored graft survival rates 
between the 2 groups. The 1-, 3-, and 5-year patient survival rates in group A and group B, 
respectively were: 100% vs. 94%, 85% vs. 63%, and 85% vs. 63% (Figure1). The 1-, 3-, and 
5-year graft survival rates in group A and B, respectively were: 100% vs. 100%, 85% vs. 
79%, and 85% vs. 79% (Figure 2). There were 10 deaths, 3 in group A and 7 in group B. The 
causes of death in group A were: cerebrovascular accident (n=1), and liver failure secondary 
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to severe progressive HCV recurrence (n=2). In group B, the causes of death were: cerebro-
vascular accident (n=1), necrotizing pancreatitis post-endoscopic retrograde cholangio-
pancreatography (n=1), self-inflicted gun shot wound to the head (n=1), and liver failure 
secondary to severe progressive HCV recurrence (n=4).  The mean time to death from OLT 
was 21.5 months in group A and 24.7 months in group B (p= ns).  CS-responsive biopsy-
proven acute rejection occurred once in 1 patient (5%) in each group. 
Secondary end points.  
The mean peak aspartate aminotransferase (AST), alanine aminotransferase (ALT), 
total bilirubin and international normalized ratio (INR) levels and the mean days to peak 
post-OLT were similar between the 2 groups. The time to transaminase peak occurred on 
POD 2 and  POD 1 in groups A and B, respectively, while the mean time to INR peak was 
<1day for both groups. Furthermore, there was no incidence of primary non-function in this 
cohort (Table 2). 
The mean weight decreased in group A and group B from baseline to one month post-
OLT. However, from 1-month to 1-year post-OLT, mean weight increased steadily in group 
A but decreased in group B, although the difference was not significant. Mean cholesterol 
levels were similar in both groups from baseline to 12 months post-OLT. The mean arterial 
pressure (MAP) in group A increased from baseline to 3 months before they started to 
decrease by 6 months post-OLT. Likewise, MAP in group B increased from baseline to 1 
month before they trended downwards by the 3
rd
 month post-OLT.   Mean FBS levels at 
baseline, 1, 3, and 12 months post-OLT were similar, except at 6 months post-OLT when 
FBS levels were significantly higher (p=0.02) in group A compared to group B. Eight 
recipients in each group developed NODM with mean FBS levels (mg/dl) of 148 and 152 in 
group A and B, respectively (Table 2).  
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A total of 12 patients in each group developed bacterial infection. No single case of 
CMV infection/disease was observed in the cohort. Furthermore, there was no recurrent HCC 
or new malignancy noted on last follow-up.  
There were more HCV recipients in group B (74%) than in group A (55%). We also 
observed an earlier peak (1 vs. 3 months post-OLT) and higher HCV PCR levels (16 million 
vs. 11.9 million, p=ns) in group A than in group B. However, the incidence and severity of 
HCV recurrence were similar in both groups based on liver biopsy results. Anti-viral 
treatment outcomes are listed in Table 3.  
Mean tacrolimus trough levels (ng/ml) were similar at 1, 3, 6, and 12 month post-
OLT in group A (11.3, 9, 7.8, 7.5) and B (8.1, 7.8, 9.4, 6), respectively. The mean duration 
on CS was 174 days in Group A. EC-MPS was given for a mean duration of 2.9 months post-
OLT in both groups. EC-MPS dose reduction was carried out for gastro-intestinal symptoms 
(diarrhea, vomiting) in 4 patients in each group; and for neutropenia in 3 and 6 recipients in 
group A and B, respectively.  EC-MPS was discontinued for GI symptoms in 1 recipient in 
each group; and for neutropenia in 2 and 1 recipient in group A and B, respectively. 
  
DISCUSSION 
Corticosteroids have been used widely for decades as part of immunosuppressive 
therapy in OLT despite their various associated long term adverse effects. In an attempt to 
reduce or avoid CS adverse effects, several transplant centers have successfully tried CS 
minimization or early CS withdrawal protocols post-OLT (4-11) and have reported similar 
graft failure rates with reduction and better control of hypertension, diabetes, obesity, and 
hypercholesterolemia, which are major risk factors known to accelerate atherosclerotic heart 
disease (10,12).  In recent years, a few CS-free immunosuppressive protocols have been 
proposed post-OLT (7-8, 13-19). Some CS-free protocols included the use of intra-operative 
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dose of CS followed by post-OLT CS-free maintenance therapy (8, 20-24). Although CS-
free protocols were reported to be safe compared to historical controls, these regimens have 
not been widely adopted by many transplant programs. Our aim was to evaluate the safety 
and efficacy of complete CS-avoidance compared to standard CS-containing 
immunosuppressive regimen consisting of basiliximab induction and tacrolimus, EC-MPS 
maintenance immunosuppression in adult OLT recipients.  
The protective effect of CS treatment in ameliorating ischemia-reperfusion (I-R) 
injury and reducing acute rejection in deceased-donor OLT has been verified in a prospective 
randomized study (25). However, this approach was questioned by animal studies which 
showed that CS given at the time of transplantation could enhance I-R injury by increasing 
DNA fragmentation, and apoptosis after reperfusion (26), and by inhibiting TNF and IL-6 
expression, which impairs cell-cycle progression, and hepatocyte regeneration (27). Our trial 
showed no difference in the incidence of I-R injury between CS-containing and CS-free 
groups, supporting Pirenne’s (10) findings that intra-operative high dose CS bolus has no 
protective effect on I-R injury.   
A recent meta-analysis of 19 randomized trials which compared CS-treated to CS-
free immunosuppression reported that the CS-free groups demonstrated a trend toward lower 
hypertension and statistically significant reduction in cholesterol levels and CMV infection 
(28). Contrary to these results our prospective randomized trial did not show any difference 
between the two groups in the incidence of hypertension, cholesterol levels or CMV 
infection. Although not significant, our results showed a tendency toward increased weight 
gain in the CS-treated group, which is an anticipated consequence of long term CS use. This 
disparity may be explained by the heterogeneity of immunosuppressive protocols used by the 
individual centers, the short period of follow up and the small sample size of the various 
trials in the meta- analysis groups. The meta-analysis also suggested that the risk of NODM 
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would be markedly lower in the CS-free arm if CS were replaced with another 
immunosuppressive agent such as an anti-IL2 antibody, polyclonal anti-T-cell antibody or 
MMF, which was not demonstrated in our study.  Our study also showed that FBS levels 
were similar between groups except at 6 months post-OLT when they were higher in the CS-
treated group. The reason for this unexpectedly higher glucose level at 6 months is unclear 
considering that most recipients in the CS-treated group were no longer on CS by 6 months 
post-OLT.  
Our study showed an overall low ACR rate of 5% and similar 1-, 3-, and 5-year 
patient and graft survival rates between CS-containing and CS-free groups. These may be 
attributed to the use of anti-IL2 induction in combination with dual CNI/MPA maintenance 
immunotherapy.   
HCV recurrence post-OLT is almost a universal phenomenon. The incidence of 
histological HCV recurrence ranges from 14% to 72% (29-30). Furthermore, a severe 
cholestatic type of recurrent HCV, characterized by rapid progression to graft failure 
requiring re-transplantation within 2 years, has been reported in about 10% of HCV 
recipients (31-32). Contrary to these findings, our study showed higher overall incidence of 
histologic HCV recurrence (81%), and severe cholestatic HCV recurrence (28%).  
Furthermore, although the mean PCR levels peaked higher and earlier in the steroid group 
compared to steroid-free group, there was no difference in the incidence and severity of HCV 
recurrence, treatment outcomes, and graft loss rates between the two groups. These findings 
are consistent with the suggestions of Eghtesad et al. (33) that viremia or avoidance of 
specific immunosuppressive drug such as CS is not critical in promoting accelerated HCV 
recurrence post-OLT. Instead, they suggested that timing and continuity of 
immunosuppressive drugs post-OLT, which regulate the overall balance between virus 
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distribution and immune responsiveness, are more important factors affecting treatment 
outcomes in HCV recipients.   
Mycophenolate mofetil has been one of the newer therapies in OLT in the last 
decade. However, MMF has been associated with diarrhea, nausea, vomiting, abdominal 
pain, etc. EC-MPS was developed in an effort to lessen these side effects. Renal transplant 
studies have shown the use of EC-MPS to be as effective and as safe as MMF (34- 35). 
However, studies on de novo use of EC-MPS in OLT recipients have been limited to 
conversion from MMF to EC-MPS (36-38). One study analyzed and showed that EC-MPS 
has similar efficacy to MMF as a primary immunosuppressant or as an MMF replacement in 
OLT recipients (39). Our data showed that EC-MPS was well tolerated with similar 
incidence of side effects between CS-treated and CS-free groups, most of which resolved 
with dose reduction. Neutropenia was observed less frequently in the CS-treated group, 
which could explain why over 90% in this group tolerated optimal dosing of EC-MPS. We 
suggest that the low incidence of neutropenia in the CS-treated group may be related to the 
effect of CS in increasing white blood cell count.  
In this study, no recipient with autoimmune-mediated liver disorder, i.e., primary 
biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis, was randomized 
in the CS-free group. It is well recognized that this subgroup of recipients may develop 
disease recurrence in the liver allograft and reported to have a higher incidence of acute and 
chronic ACR and perhaps may benefit from continuous, long term CS immunoprophylaxis 
(40-41). Consequently, extra caution should be exercised when selecting recipients who can 
safely be included in a completely CS-free regimen.   
 In conclusion, our analysis suggests that complete CS avoidance in adult OLT using 
basiliximab induction with CNI and EC-MPS maintenance is as safe and as effective as 
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standard CS-containing immunosuppression when evaluating for graft function, acute 
rejection, and patient and graft survival.  Contrary to other studies, our results did not show 
any significant difference between CS-treated and CS-free groups in the incidence of 
hypertension, hypercholesterolemia, NODM, and weight gain. Furthermore, our data did not 
validate the common belief that CS-free immunosuppression has a beneficial effect in 
reducing the incidence, severity or degree of progression of HCV recurrence post-OLT.  
 
MATERIALS AND METHODS 
Institutional Review Board approval from TJUH was granted and informed consent 
was obtained from all subjects enrolled in this study, conforming to the ethical guidelines of 
the Declaration of Helsinki. Between February 2006 and November 2007, forty adult 
recipients of deceased donor primary OLT at TJUH were enrolled into this prospective, 
controlled, randomized, non-blinded, pilot trial. The primary objective was to assess the 
efficacy and safety of a completely CS-free immunosuppressive regimen in OLT, by 
comparing graft and patient survival rates and incidence and treatment of acute cellular 
rejection (ACR), between recipients treated with and without CS. The secondary objective 
was to compare the incidence of CS-related metabolic complications and HCV recurrence 
between recipients treated with and without CS.   Common side effects associated with 
enteric-coated mycophenolate sodium (EC-MPS) use, i.e., neutropenia and gastro-intestinal 
symptoms, were also evaluated. 
Inclusion criteria: adult recipients of primary cadaveric OLT between 18- 72 years 
old, liver graft cold ischemia time of <20 hours, and women of childbearing potential with 
negative pregnancy test.  The exclusion criteria included: multiple organ transplant 
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recipients, women of childbearing potential not using the prescribed contraceptive 
methods, and use of any other investigational agent within 30 days prior to enrollment.    
All recipients received basiliximab 20 mg IV intra-operatively and on post-operative 
day (POD) 4. Maintenance immunosuppression included tacrolimus and EC-MPS. 
Tacrolimus was started at 0.10 mg/kg/day by mouth (PO) or nasogastric tube (NGT) in 2 
divided doses, within 48 hrs after reperfusion. The dose was adjusted to achieve target trough 
level 8-12 ng/ml in first month post-OLT, and 5-8 ng/ml, thereafter. All recipients received 
MMF 1 g every 12 hours via NGT until they could take oral medications, after which they 
were switched to EC-MPS 720 mg PO twice daily for three months post-OLT. 
Recipients were randomized into either treatment arms: Control arm (group A) -
standard immunosuppression with CS; and CS-free arm (group B) - standard 
immunosuppression without CS. Group A received methylprednisolone 1 g IV intra-
operatively followed by a taper schedule as follows: methylprednisolone 50 mg IV every 6 
hours on day 1; 40 mg IV every 6 hours on day 2; 30 mg IV every 6 hours on day 3; 20 mg 
IV every 6 hours on day 4; 20 mg IV every 12 hours on days 5; and thereafter, prednisone 20 
mg PO daily which was tapered off by 6 months post-OLT. Group A and B recipients were 
on maintenance CNI monotherapy by 6 months and 3 months post-OLT, respectively. 
All recipients received cytomegalovirus (CMV) prophylaxis with IV gancyclovir or 
valgancyclovir 450 mg PO daily for at least 3 months. They also received prophylactic doses 
of trimethoprim sulfa 3 times weekly and nystatin swish and swallow 3 times daily. 
Liver biopsies were performed according to protocol intra-operatively, between days 
7 and 21 post-OLT and at 3-6 months post-OLT, and when clinically indicated. For HCV (+) 
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recipients, quantitative HCV RNA PCR serum levels were performed at baseline, 0.5, 1, 3, 
and 6 months post-OLT.   
Biopsy-proven ACR using the Banff Classification (42) was treated in both groups 
with methylprednisolone 1 g IV followed by a 5-day CS taper as described above. For 
recipients in group B who received CS for ACR, prednisone was tapered off by the third 
month after CS initiation. The protocol also required a repeat biopsy if there was no 
improvement in the liver function test at the end of CS taper.  
A diagnosis of HCV recurrence was made based on liver biopsy findings and serum 
HCV RNA titers. Recipients with HCV recurrence were treated according to TJUH protocol 
as described below. Abnormal liver function tests were evaluated by hepatic ultrasound, and 
percutaneous liver biopsy. The TJUH protocol follows the modified Scheuer scoring system 
(43-44) to evaluate the need for anti-viral treatment in chronic hepatitis post-OLT. If the liver 
biopsy shows total score of  >4 for necro-inflammatory activity (greater than mild portal and 
lobular inflammation) or > stage 1 (enlarged and fibrotic portal tracts), treatment with Peg-
Interferon 180μg subcutaneously weekly for 2 weeks would be started. If the recipient 
tolerates peg-interferon without hematologic or neuro-psychiatric complications, ribavirin is 
added to Peg-interferon for a total duration of 48 weeks. 
Weight, total cholesterol, fasting blood sugar (FBS), and mean arterial pressure 
(MAP) levels were measured and recorded at baseline, 1, 3, 6 and 12 months post-OLT.  
New onset diabetes mellitus (NODM) was defined as FBS ≥ 126 mg/dl (7 mmol/l), with 
fasting defined as no caloric intake for at least 8 hours.  
STATISTICAL ANALYSIS:  Statistical analysis was done to demonstrate 
equivalence or non-inferiority of the CS-free immunosuppressive regimen compared to the 
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standard protocol with CS for both primary and secondary end points. All continuous 
variables were summarized with mean and standard error and all categorical variables 
summarized as percentages.  Statistical significance for each test was reported at p ≤ 0.05.  
For continuous values, each group was compared using a two-tailed, independent Student’s t-
test assuming equal or unequal variance based on the results of an F-test.  Each categorical 
variable was compared using a two-tailed Fisher’s exact test.  Survival analysis was done 
with Kaplan-Meier and significance was determined using a log-rank test.  Analysis was 
performed using XLSTAT 2008 (Addinsoft, 2008) for Microsoft Excel. 
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TABLES 
Table 1. Recipient & Donor demographics and baseline (pre-OLT) characteristics  
        Donor Variables Group A Group B    p-value 
Donor Age (years), mean± SD  48.1  ± 4.3 45.5  ± 3.5     ns 
Donor Sex (M/F), n 12 /8  12 / 7      ns 
Donor Race, n  Caucasian: 13  
Non-Caucasian: 7  
Caucasian: 13  
Non-Caucasian: 6  
    ns 
Donor HCV +, n  1  3      ns 
    
       Recipient Variables     
Age, (years), mean ± SE 50.40 ±  56.2 ± 1.1    0.05 
Sex (M/F), n 15 / 5  14 / 5      ns 
Race, n Caucasian: 16  
Non-Caucasian: 4  
Caucasian: 16  
Non-Caucasian: 3  
    ns 
* Primary Diagnosis: n Cryptogenic: 2 
HCV: 11 
HBV: 2 
PSC: 2 
HCC: 10 
LC: 3 
NASH: 1 
Cryptogenic: 1 
HCV: 14 
HBV: 2 
Budd-Chiari: 1 
HCC: 11 
LC: 6 
    ns 
MELD Score, mean ± SD 23.2 ± 1.5 24.4 ± 2     ns 
DM, n  5  4      ns 
Hypertension, n  7  7      ns 
Weight (lbs), mean ± SD 173.8 ± 9.6 171.5 ± 7.7     ns 
        
Recipient Peri-operative Data        
(mean ± SE) 
   
Cold ischemia time (h:min)  7:25 ± 0:23 7:52 ± 0:38      ns 
Intra-operative red blood cell 
transfusion (units)   
7.9 ± 1.6 9.5 ± 1.5      ns 
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Total OR time (h:mm)   9:10 ± 1:19 8:44 ± 1:17      ns 
Intensive care unit (days)   3.6 ± 0.39 5.8 ± 1.27      ns 
Hospital length of stay (days)   16.7 ± 1.7 28.6 ± 5.1    0.04 
    
    
* Some patients presented multiple diagnoses. HCV, hepatitis C virus; PSC, primary 
sclerosing cholangitis; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; NASH, 
nonalcoholic steatohepatitis; LC, Laennec’s cirrhosis 
 
 
 
Table 2. Recipient Metabolic Panels 
 
            Clinical Variables Group A  Group B p-value  
Liver function tests    
      Peak AST (IU/L) 2,357 1,503 ns 
      Peak ALT (IU/L) 1,151  813 ns 
      Total Bilirubin (mg/dl)  9.5 11.8 ns 
      INR 2.61 2.79 ns 
Mean weight (lbs)           
      Baseline 174 167 ns 
      1-month post-OLT 165 163 ns 
      3-months post-OLT 168 157 ns 
      6-months post-OLT 176 156 ns 
      12-months post-OLT 181 157 ns 
Cholesterol (mg/dl)    
      Baseline 94 91 ns 
      1-month post-OLT 155 157 ns 
      3-months post-OLT 151 143 ns 
      6-months post-OLT 165 149 ns 
      12-months post-OLT 146 160 ns 
Mean arterial pressure (MAP)    
      Baseline 84 89 ns 
      1-month post-OLT 93 96 ns 
      3-months post-OLT 99 91 ns 
      6-months post-OLT 98 94 ns 
      12-months post-OLT 96 91 ns 
  Fasting blood sugar (mg/dl)    
      Baseline 148 148 ns 
      1-month post-OLT 111 103 ns 
      3-months post-OLT 117 106 ns 
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      6-months post-OLT 144 98 0.02 
      12-months post-OLT 147 112 ns 
 
 
 
 
 
 
 
Table 3.  Hepatitis Recurrence  
 
       Clinical Variables Group A              Group B  p-value 
Total number of HCV recipients 11/20 (55%) 14/19 (74%)       ns 
Mean HCV RNA PCR               
     Pre-OLT           0.48 M         0.45 M       ns 
     2 weeks post-OLT           5.8 M         0.83 M       ns 
     1 month post-OLT           15.9 M         3.7 M       ns 
     3 months post-OLT           12.3 M         11.9 M       ns 
     6 months post-OLT           11.1 M         5.5 M       ns 
Treatment for HCV recurrence 7/11 (64%) 9/14 (64%)       ns 
No Treatment for HCV recurrence 4/11 (36%) 5/14 (36%)       ns 
Mean duration of treatment (wks) 38.5 (4-52) 19.3 (2-46) 0.048 
Sustained viral response (SVR) 2/11 (18%) 2/14 (14%)       ns 
Non-responder to treatment 3/11 (27%) 3/14 (21%)       ns 
HCV progression to cirrhosis  3/11 (27%) 4/14 (29%)       ns 
Mean OLT to death interval (months) 25.9 25.4       ns 
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